-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Felodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group
Category:
发布时间：2025-04-10
【概要描述】
Recently, the felodipine active pharmaceutical ingredient developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been approved by the state and registered as an API for use in marketed dosage forms.
Recently, the felodipine active pharmaceutical ingredient developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has received national approval and been registered as an API for use in marketed dosage forms.
To date, the Group has received approval for a total of 72 active pharmaceutical ingredient (API) products. As a key R&D and industrialization hub for the Group’s integrated API–formulation development strategy, Guangxiang Pharmaceutical currently boasts 41 bulk and specialty APIs.
According to available information, felodipine is primarily used for the treatment of mild to moderate primary hypertension and stable angina pectoris.
Previously, Shijiazhuang Sihua Pharmaceutical’s 5 mg felodipine extended-release tablets were approved by the National Medical Products Administration in January 2023, which was deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs, and the product was subsequently selected in the eighth round of national centralized drug procurement in April of the same year. The approval of the felodipine API this time will further strengthen the Group’s integrated, synergistic capabilities in both API and formulation development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091